Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CUE Cue Biopharma	$0.74 -6.1%	$0.70	$0.45 ▼ $1.99	$55.83M	1.42	413,058 shs	233,740 shs
DBVT DBV Technologies	$9.19 -0.3%	$9.24	$2.20 ▼ $12.78	$251.58M	-0.63	191,385 shs	12,742 shs
DMAC DiaMedica Therapeutics	$3.84 +0.8%	$3.99	$2.65 ▼ $6.82	$164.66M	1.23	98,079 shs	3.18 million shs
NBTX Nanobiotix	$4.61 -2.5%	$4.01	$2.76 ▼ $6.00	$217.27M	0.35	15,479 shs	4,345 shs

Beginner's Guide To Retirement Stocks

Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CUE Cue Biopharma	0.00%	+5.75%	+11.90%	-18.66%	-40.24%
DBVT DBV Technologies	0.00%	-2.29%	+10.66%	+34.68%	+129.34%
DMAC DiaMedica Therapeutics	0.00%	+6.37%	-6.34%	+1.32%	+30.17%
NBTX Nanobiotix	0.00%	+3.13%	+12.27%	+28.77%	-7.80%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CUE Cue Biopharma	4.0406 of 5 stars	3.5	2.0	4.7	2.6	0.8	0.6
DBVT DBV Technologies	3.689 of 5 stars	4.4	3.0	0.0	2.7	2.5	0.6
DMAC DiaMedica Therapeutics	1.3618 of 5 stars	3.5	1.0	0.0	2.4	0.0	0.0
NBTX Nanobiotix	2.4292 of 5 stars	3.3	3.0	0.0	3.8	0.0	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CUE Cue Biopharma	3.00	Buy	$3.00	304.86% Upside
DBVT DBV Technologies	2.80	Moderate Buy	$14.75	60.59% Upside
DMAC DiaMedica Therapeutics	3.00	Buy	$8.00	108.33% Upside
NBTX Nanobiotix	2.50	Moderate Buy	$8.00	73.54% Upside

Current Analyst Ratings Breakdown

Latest CUE, DBVT, NBTX, and DMAC Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/26/2025	DBVT DBV Technologies	Lifesci Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
6/26/2025	DBVT DBV Technologies	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$21.00
5/29/2025	DBVT DBV Technologies	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Sell	$7.25
5/29/2025	DMAC DiaMedica Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00
5/27/2025	DBVT DBV Technologies	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform
5/27/2025	DBVT DBV Technologies	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Market Outperform ➝ Market Outperform	$15.00 ➝ $21.00
5/5/2025	DBVT DBV Technologies	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$7.00 ➝ $16.00
5/1/2025	DBVT DBV Technologies	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Market Outperform ➝ Market Outperform	$10.00 ➝ $15.00
4/4/2025	NBTX Nanobiotix	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$12.00 ➝ $8.00

(Data available from 6/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CUE Cue Biopharma	$9.29M	6.01	N/A	N/A	$0.28 per share	2.65
DBVT DBV Technologies	$4.15M	60.62	N/A	N/A	$1.42 per share	6.47
DMAC DiaMedica Therapeutics	N/A	N/A	N/A	N/A	$0.95 per share	N/A
NBTX Nanobiotix	$39.18M	5.55	N/A	N/A	($1.51) per share	-3.05

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CUE Cue Biopharma	-$40.67M	-$0.67	N/A	N/A	N/A	-507.87%	-228.43%	-114.66%	8/13/2025 (Estimated)
DBVT DBV Technologies	-$113.92M	-$4.92	N/A	N/A	N/A	-3,249.99%	-278.24%	-140.54%	7/29/2025 (Estimated)
DMAC DiaMedica Therapeutics	-$24.44M	-$0.64	N/A	N/A	N/A	N/A	-61.35%	-55.53%	8/6/2025 (Estimated)
NBTX Nanobiotix	-$73.73M	N/A	0.00	N/A	N/A	N/A	N/A	N/A	9/16/2025 (Estimated)

Latest CUE, DBVT, NBTX, and DMAC Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/13/2025	Q1 2025	DMAC DiaMedica Therapeutics	-$0.18	-$0.18	N/A	-$0.18	N/A	N/A
5/12/2025	Q1 2025	CUE Cue Biopharma	-$0.14	-$0.17	-$0.03	-$0.17	$0.90 million	$0.42 million
4/11/2025	Q4 2024	DBVT DBV Technologies	N/A	-$1.10	N/A	-$1.10	N/A	$0.51 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CUE Cue Biopharma	N/A	N/A	N/A	N/A	N/A
DBVT DBV Technologies	N/A	N/A	N/A	N/A	N/A
DMAC DiaMedica Therapeutics	N/A	N/A	N/A	N/A	N/A
NBTX Nanobiotix	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CUE Cue Biopharma	N/A	1.03	1.03
DBVT DBV Technologies	N/A	0.72	0.72
DMAC DiaMedica Therapeutics	N/A	8.02	8.02
NBTX Nanobiotix	N/A	1.04	1.04

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CUE Cue Biopharma	35.04%
DBVT DBV Technologies	71.74%
DMAC DiaMedica Therapeutics	10.12%
NBTX Nanobiotix	38.81%

Insider Ownership

Company	Insider Ownership
CUE Cue Biopharma	12.26%
DBVT DBV Technologies	1.44%
DMAC DiaMedica Therapeutics	7.30%
NBTX Nanobiotix	3.45%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CUE Cue Biopharma	60	75.35 million	66.11 million	Optionable
DBVT DBV Technologies	80	27.39 million	27.00 million	Optionable
DMAC DiaMedica Therapeutics	20	42.88 million	39.75 million	Optionable
NBTX Nanobiotix	100	47.13 million	45.51 million	Not Optionable

CUE, DBVT, NBTX, and DMAC Headlines

Recent News About These Companies

Short Interest in Nanobiotix S.A. (NASDAQ:NBTX) Declines By 89.1%

June 11, 2025 | marketbeat.com

Nanobiotix (NASDAQ:NBTX) Stock Price Up 1.1% - Here's Why

June 4, 2025 | marketbeat.com

Short Interest in Nanobiotix S.A. (NASDAQ:NBTX) Grows By 1,197.9%

May 30, 2025 | marketbeat.com

NANOBIOTIX to Participate in the Jefferies Global Healthcare Investor Conference

May 28, 2025 | globenewswire.com

Nanobiotix Provides First Quarter 2025 Operational and Financial Update

May 21, 2025 | globenewswire.com

Nanobiotix to Participate in the H.C. Wainwright 3rd Annual BioConnect Investor Conference at NASDAQ

May 12, 2025 | globenewswire.com

Nanobiotix Reveals Favorable Results Of JNJ-1900 Study Pancreatic Cancer; Seeks Further Evaluation

May 5, 2025 | finanznachrichten.de

Nanobiotix Announces Full Results From Completed Phase 1 Study Evaluating JNJ-1900 (NBTXR3) in Pancreatic Cancer

May 5, 2025 | globenewswire.com

Nanobiotix Announces Presentation of Full Results From Completed Phase 1 Study Evaluating JNJ-1900 (NBTXR3) in Pancreatic Cancer Followed by a Conference Call

April 30, 2025 | globenewswire.com

Nanobiotix price target lowered to $8 from $12 at Guggenheim

April 5, 2025 | markets.businessinsider.com

Nanobiotix (NBTX) Gets a Hold from UBS

April 5, 2025 | markets.businessinsider.com

Nanobiotix S.A. (NBTX) Q4 2024 Earnings Call Transcript

April 3, 2025 | seekingalpha.com

NANOBIOTIX Provides Business Update and Reports Full Year 2024 Financial Results

April 2, 2025 | globenewswire.com

Analysts Have Conflicting Sentiments on These Healthcare Companies: Pfizer (PFE), Nanobiotix (NBTX) and PTC Therapeutics (PTCT)

April 2, 2025 | theglobeandmail.com

NANOBIOTIX to Announce Fourth Quarter and Full Year 2024 Operational and Financial Update on April 2, 2025

March 31, 2025 | globenewswire.com

Nanobiotix reports promising NSCLC treatment study results

March 29, 2025 | investing.com

Nanobiotix Announces First Data From the Completed Dose Escalation Part of a Phase 1 Study Evaluating NBTXR3 (JNJ-1900) as a 2L+ Therapy for Patients With Locally Advanced NSCLC

March 27, 2025 | globenewswire.com

NANOBIOTIX Announces Presentation of Data From Two Phase 1 Studies Evaluating JNJ-1900 (NBTXR3)

March 21, 2025 | djournal.comD

NANOBIOTIX Announces Presentation of Data From Two Phase 1 Studies Evaluating JNJ-1900 (NBTXR3) at the European Lung Cancer Conference

March 20, 2025 | globenewswire.com

Nanobiotix amends global licensing agreement with Janssen Pharmaceutica

March 18, 2025 | markets.businessinsider.com

NANOBIOTIX Strengthens Financial Position Through Amendment of Global Licensing Agreement for JNJ-1900 (NBTXR3) and Extends Cash Visibility to Mid-2026

March 17, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

CUE, DBVT, NBTX, and DMAC Company Descriptions

Cue Biopharma NASDAQ:CUE

$0.74 -0.05 (-6.13%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$0.76 +0.02 (+3.10%)

As of 06/27/2025 07:55 PM Eastern

Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops a novel class of injectable therapeutics to selectively engage and modulate targeted, disease relevant T cells directly within the patient's body. Its lead drug product candidate is CUE-101 for the treatment of human papilloma virus (HPV16+)-driven recurrent/metastatic head and neck cancer. The company is also developing CUE-102 targets Wilms' Tumor 1 protein in various cancers; CUE-103, a CUE-100 series drug product candidate; and Neo-STAT and RDI-STAT programs outside of oncology, including CUE-200, CUE-300, and CUE-400 series. It has collaboration agreements with LG Chem, Ltd. for the development of Immuno-STATs focused in the field of oncology; strategic collaboration and option agreement with Ono Pharmaceutical Co., Ltd. to advance CUE-401 for the treatment of autoimmune and inflammatory diseases; and license agreement with Albert Einstein College of Medicine. The company was formerly known as Imagen Biopharma, Inc. and changed its name to Cue Biopharma, Inc. in October 2016. Cue Biopharma, Inc. was incorporated in 2014 and is headquartered in Boston, Massachusetts.

DBV Technologies NASDAQ:DBVT

$9.18 -0.03 (-0.27%)

Closing price 06/27/2025 03:58 PM Eastern

Extended Trading

$9.18 0.00 (0.00%)

As of 06/27/2025 05:48 PM Eastern

DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis. The company's earlier stage research programs includes vaccine for the respiratory syncytial virus, potential treatments for inflammatory bowel disease, celiac disease, and type I diabetes. In addition, it develops Viaskin technology platform, a platform to potentially treat food allergy. The company has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Montrouge, France.

DiaMedica Therapeutics NASDAQ:DMAC

$3.84 +0.03 (+0.79%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$3.83 -0.01 (-0.26%)

As of 06/27/2025 05:50 PM Eastern

DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from serious diseases with a focus on acute ischemic stroke. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase II/III trials for the treatment of acute ischemic stroke, as well as that is in Phase 2 to treat cardio-renal disease. The company also develops DM300, which is in preclinical stage for the treatment of severe inflammatory diseases. In addition, it develops treatment for neurological disease. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.

Nanobiotix NASDAQ:NBTX

$4.73 0.00 (-0.02%)

As of 06/27/2025 04:00 PM Eastern

Nanobiotix S.A., a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. The company has a partnership with Lian Oncology Limited to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand. Nanobiotix S.A. was incorporated in 2003 and is headquartered in Paris, France.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time